Please login to the form below

Not currently logged in

Crohn's disease

This page shows the latest Crohn's disease news and features for those working in and with pharma, biotech and healthcare.

AbbVie’s upadacitinib aces phase III trial

AbbVie’s upadacitinib aces phase III trial

AbbVie’ s upadacitinib aces phase III trial. Arthritis drug outperformed both placebo and Humira in the study. ... even climb as high as $5bn at peak if it also shows its worth in follow-up indications like psoriatic arthritis, Crohn's disease,

Latest news

More from news
Approximately 19 fully matching, plus 150 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    for local administration for the treatment of complex perianal fistulas in patients with Crohn’s disease. ... Option exercise (2 options). 640. TiGenix/Takeda. Cx601, lead asset, allogeneic expanded adipose-derived stem cells (eASC) locally

  • The good, the bad and the ugly The good, the bad and the ugly

    Tecfidera (MS) and Spinraza (Spinal Muscular Atrophy) are expected to generate big sales, while Tysabril (MS and Crohn’s Disease) and Avonex (MS) are expected to see sales drop due to ... However, there is a movement towards greater research in this

  • Managing medication non-adherence Managing medication non-adherence

    Autoimmune conditions such as Crohn’s disease can flare up through an imbalance of things like stress, lack of sleep or overworking - not just as a direct consequence of nonadherence to ... These will be used to aid in decision-making and help

  • Deal Watch January 2017 Deal Watch January 2017

    Pipping Sanofi to the post, the acquisition brings a high margin rare disease portfolio at the cost of $280 per share representing a 23% premium. ... Assembly Biosciences. Allergan. Exclusive global licence . 2 pc candidates for ulcerative colitis

  • Deal Watch October 2016 Deal Watch October 2016

    How many Beatles song titles did you spot in this month's Deal Watch report? ... Allergan (US). Licence. Anti-interleukin 23 MAb in phase IIb for Crohn's Disease.

More from intelligence
Approximately 0 fully matching, plus 19 partially matching documents found.

Latest appointments

  • TiGenix appoints Dr Marie Paule Richard TiGenix appoints Dr Marie Paule Richard

    in phase III trials for complex perianal fistulas in Crohn's disease.

  • Ex J&J VP joins board of Immune Ex J&J VP joins board of Immune

    Immune will benefit from Durrant's knowledged of the iundstry gained during time in roles such as worldwide VP at Johnson &Johnson and VP, Pharmacia until its acquisition by Pfizer. ... Its lead product candidate is bertilimumab, which is in clinical

  • Former Novartis president joins Qu Biologics Former Novartis president joins Qu Biologics

    His senior industry experience will support Qu Biologics' plans to advance the development of its investigational immunotherapies for treatments such as Crohn's disease. “ ... Bob Pelzer's wealth of leadership experience with Novartis and DuPont will

More from appointments
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • Living with Crohn's disease: a patient perspective

    Crohn’ s disease is a form of Inflammatory Bowel Disease (IBD), which causes inflammation of the digestive system or gut. ... Living with Crohn’ s: challenges in diagnosis. Our understanding of the causes of Crohn’ s disease is improving.

  • Patient Perspective: Crohn's disease

    Patient Perspective: Crohn's disease. At Synergy Vision, we aim to make a difference to patients. ... In the first of our series on patient perspectives we are talking about Crohn's disease.

  • Patient Persepective: Autoimmune Disease

    Patient Persepective: Autoimmune Disease. Autoimmune diseases affect 1– 5% of the World’ s population and have varied symptoms and causes. ... Here we explore with Lois what it is like to live with the symptoms of autoimmune disease, including


    THE OTHER SIDE OF… CROHN’ S DISEASE. “ After visiting about seven doctors in two different countries, I am confident to say that all can align on 2– 3 points at most”. ... Meet Irene. Like millions of others worldwide (and an estimated 115, 000

  • Living with Crohn's Report

    Living with Crohn's Report. Are you looking for a deeper understanding of the emotional needs, behaviours and treatment programmes of patients living with Crohn’ s Disease? ... Living with Crohn’ s is a new syndicated report designed to provide an in

More from PMHub
Approximately 5 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company

emotive. is an award-winning healthcare communications agency working with leading global and EMEA companies in life sciences including medical device...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...